Patent intelligence · US
US 2022031686
Treatment of Migraine
Treatment of Migraine
Patent details — US 2022031686
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 3, 2022
- Expiration
- Jan 29, 2042
- Applicant
- ALLERGAN PHARMACEUTICALS INT LTD [IE]
- CPC classes
- A61K 31/ 4545 A I, A61K/314545, A61P 25/ 06 A I, A61P/2506
Quick answer
US 2022031686 (Treatment of Migraine) is held by ALLERGAN PHARMACEUTICALS INT LTD [IE]. Status: granted. Granted Feb 3, 2022. Expires Jan 29, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ALLERGAN PHARMACEUTICALS INT LTD [IE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 4545 A I, A61K/314545, A61P 25/ 06 A I, A61P/2506
More from ALLERGAN PHARMACEUTICALS INT LTD [IE]
Related pharmaceutical patents in our USPTO index.
-
US 12383545
TREATMENT OF MIGRAINE
granted -
US 2025064788
TREATMENT OF MIGRAINE
granted -
US 2024180883
TREATMENT OF MIGRAINE
granted -
WO 2024081718
ANTAGONISTE DU RÉCEPTEUR CGRP POUR LE TRAITEMENT DE LA MIGRAINE
granted -
CA 3244873
TRAITEMENT PRÉVENTIF DE LA MIGRAINE
granted -
WO 2023077094
TRAITEMENT D'UN TROUBLE DÉPRESSIF MAJEUR
granted -
US 2023130736
METHODS OF TREATING MIGRAINE
granted -
US 2022380379
PHARMACEUTICAL COMPOUNDS
granted
Frequently asked questions
What is US patent 2022031686?
US 2022031686 (Treatment of Migraine) is held by ALLERGAN PHARMACEUTICALS INT LTD [IE]. Status: granted. Granted Feb 3, 2022. Expires Jan 29, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2022031686?
ALLERGAN PHARMACEUTICALS INT LTD [IE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does US 2022031686 expire?
Our index shows an expiration date of Jan 29, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.